Literature DB >> 17191149

The effect of natural killer cell killer Ig-like receptor alloreactivity on the outcome of bone marrow stem cell transplantation for severe combined immunodeficiency (SCID).

M D Keller1, D F Chen, S A Condron, N Liu, N L Reinsmoen, R H Buckley.   

Abstract

Natural killer (NK) cell alloreactions against recipient cells in the setting of bone marrow transplantation have been associated with decreased rates of graft-versus-host disease (GVHD) and improved survival in transplant recipients with myeloid leukemia. These alloreactions are predicted by the absence of recipient HLA class I ligands for donor inhibitory killer Ig-like receptors (KIR). We hypothesized that donor NK cell alloreactions against recipient cells may affect the development of T and B-cell functions and incidence of GVHD in infants with severe combined immunodeficiency (SCID). Of the 156 patients with SCID who had received related bone marrow transplants without pretransplant chemotherapy or posttransplant GVHD prophylaxis, 137 patient-donor pairs were evaluated for the absence of recipient HLA class I ligands for donor inhibitory KIR. Analysis showed that the absence of a KIR ligand had no effect on the incidence or severity of GVHD (RR [corrected] = 0.95, p = 0.84), development of T-cell function (RR [corrected] = 1.05, p = 0.69), production of IgA (p = 0.46) or IgM (p = 0.33), or on 5-year survival (RR [corrected] = 1.21, p = 0.10). Further, in patients possessing native NK cells, the absence of KIR ligands in donors for recipient-inhibitory KIR did not alter transplantation outcomes. This study suggests that inhibitory KIR/HLA interactions do not play a significant role in bone marrow transplantation for SCID.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17191149     DOI: 10.1007/s10875-006-9058-7

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  37 in total

Review 1.  MHC class I molecules and KIRs in human history, health and survival.

Authors:  Peter Parham
Journal:  Nat Rev Immunol       Date:  2005-03       Impact factor: 53.106

2.  Hematopoietic stem cell transplantation for severe combined immunodeficiency in the neonatal period leads to superior thymic output and improved survival.

Authors:  Laurie A Myers; Dhavalkumar D Patel; Jennifer M Puck; Rebecca H Buckley
Journal:  Blood       Date:  2002-02-01       Impact factor: 22.113

3.  Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors.

Authors:  Sebastian Giebel; Franco Locatelli; Teresa Lamparelli; Andrea Velardi; Stella Davies; Guido Frumento; Rita Maccario; Federico Bonetti; Jerzy Wojnar; Miryam Martinetti; Francesco Frassoni; Giovanna Giorgiani; Andrea Bacigalupo; Jerzy Holowiecki
Journal:  Blood       Date:  2003-04-10       Impact factor: 22.113

4.  Primary immunodeficiencies in Switzerland: first report of the national registry in adults and children.

Authors:  O Ryser; A Morell; W H Hitzig
Journal:  J Clin Immunol       Date:  1988-11       Impact factor: 8.317

5.  Determinants of antileukemia effects of allogeneic NK cells.

Authors:  Wing Leung; Rekha Iyengar; Victoria Turner; Peter Lang; Peter Bader; Paul Conn; Dietrich Niethammer; Rupert Handgretinger
Journal:  J Immunol       Date:  2004-01-01       Impact factor: 5.422

6.  Does haploidentical transplantation in children with primary immunodeficiencies have the potential to exploit donor NK cell alloreactivity?

Authors:  L Dal-Cortivo; M Ouachée-Chardin; I Hirsch; S Blanche; A Fischer; M Cavazzana-Calvo; S Caillat-Zucman
Journal:  Bone Marrow Transplant       Date:  2004-12       Impact factor: 5.483

Review 7.  Natural killer cell receptors: new biology and insights into the graft-versus-leukemia effect.

Authors:  Sherif S Farag; Todd A Fehniger; Loredana Ruggeri; Andrea Velardi; Michael A Caligiuri
Journal:  Blood       Date:  2002-09-15       Impact factor: 22.113

8.  Immune reconstitution in ADA-SCID after PBL gene therapy and discontinuation of enzyme replacement.

Authors:  Alessandro Aiuti; Sergio Vai; Alessandra Mortellaro; Giulia Casorati; Francesca Ficara; Grazia Andolfi; Giuliana Ferrari; Antonella Tabucchi; Filippo Carlucci; Hans D Ochs; Luigi D Notarangelo; Maria Grazia Roncarolo; Claudio Bordignon
Journal:  Nat Med       Date:  2002-05       Impact factor: 53.440

9.  Peculiar immunobiology of bone marrow allografts. II. Rejection of parental grafts by resistant F 1 hybrid mice.

Authors:  G Cudkowicz; M Bennett
Journal:  J Exp Med       Date:  1971-12-01       Impact factor: 14.307

10.  Roles for HLA and KIR polymorphisms in natural killer cell repertoire selection and modulation of effector function.

Authors:  Makoto Yawata; Nobuyo Yawata; Monia Draghi; Ann-Margaret Little; Fotini Partheniou; Peter Parham
Journal:  J Exp Med       Date:  2006-03-13       Impact factor: 14.307

View more
  3 in total

Review 1.  Current Knowledge and Priorities for Future Research in Late Effects after Hematopoietic Stem Cell Transplantation (HCT) for Severe Combined Immunodeficiency Patients: A Consensus Statement from the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects after Pediatric HCT.

Authors:  Jennifer Heimall; Jennifer Puck; Rebecca Buckley; Thomas A Fleisher; Andrew R Gennery; Benedicte Neven; Mary Slatter; Elie Haddad; Luigi D Notarangelo; K Scott Baker; Andrew C Dietz; Christine Duncan; Michael A Pulsipher; Mort J Cowan
Journal:  Biol Blood Marrow Transplant       Date:  2017-01-06       Impact factor: 5.742

2.  A novel approach for quantification of KIR expression in healthy donors and pediatric recipients of hematopoietic SCTs.

Authors:  X Chen; J Knowles; R C Barfield; K A Kasow; R Madden; P Woodard; D K Srivastava; E M Horwitz; R Handgretinger; G A Hale
Journal:  Bone Marrow Transplant       Date:  2008-11-24       Impact factor: 5.483

3.  Importance of killer immunoglobulin-like receptors in allogeneic hematopoietic stem cell transplantation.

Authors:  Danilo Santana Alessio Franceschi; Cármino Antonio de Souza; Francisco José Penteado Aranha; Daniela Maira Cardozo; Ana Maria Sell; Jeane Eliete Laguila Visentainer
Journal:  Rev Bras Hematol Hemoter       Date:  2011
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.